Pancreatic cancer laboratory tests: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 3: Line 3:
{{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}};{{PSD}}
{{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}};{{PSD}}
==Overview==
==Overview==
Laboratory findings consistent with the diagnosis of pancreatic [[cancer]] include abnormal [[liver function tests]] and elevated [[CA 19-9]] and [[CEA]] levels.
Laboratory findings consistent with the diagnosis of pancreatic [[cancer]] include abnormal [[liver function tests|liver function tests,]] elevated serum bilirubin levels (conjugated and total), elevated alkaline phosphatase levels and mild normocytic normochromic anemia. Patients may have evidence of malnutrition and elevated [[CA 19-9]] levels.


==Laboratory Findings==
==Laboratory Findings==
Routine laboratory tests are often non specific  Common abnormalities include an:   elevated serum bilirubin (conjugated and total) elevated alkaline phosphatase levels elevated gamma-glutamyl transpeptidase elevated aspartate aminotransferase and alanine aminotransferase to a lesser extent  CBC shows a mild normochromic anemia  Thrombocytosis  Serum amylase and/or lipase levels are normal/elevated  laboratory evidence of malnutrition: low serum albumin or cholesterol level).   CA 19-9 antigen is a sialylated oligosaccharide that is most commonly found on circulating mucins in cancer patients.<sup> [[null 39]] </sup>It is also normally present within the cells of the biliary tract and can be elevated in acute or chronic biliary disease  The reference range of CA 19-9 is less than 33-37 U/mL in most laboratories.  Of patients with pancreatic carcinoma, 75-85% have elevated CA 19-9 levels.  In the absence of biliary obstruction, intrinsic liver disease, or benign pancreatic disease, a CA 19-9 value of greater than 100 U/mL is highly specific for malignancy, usually pancreatic. Evaluation of CA 19-9 levels has been used as an adjunct to imaging studies for helping to determine the resectability potential of pancreatic carcinoma. An elevated Patients presenting with low levels of CA 19-9 (< 100 IU) are unlikely to have occult metastatic disease and therefore may not need a staging laparoscopy prior to resection if other imaging shows no advanced disease.  Additionally, during surgical, chemotherapeutic, and/or radiotherapeutic treatment for pancreatic cancer, a falling CA 19-9 seems to be a useful surrogate finding for clinical response to the therapy.  If biliary obstruction is not present, a rising CA 19-9 suggests progressive disease.  Preoperative CA 19-9 levels may be of prognostic value, with high levels indicating poorer outcome and less chance of resectability.<sup>[[null 40], [null 41]] </sup>Preoperative values above 50 U/mL have been shown to be associated with higher chances of recurrence.
* Routine laboratory tests in pancreatic cancer patients are often non specific.
* Common abnormalities include:  
** Elevated serum bilirubin (conjugated and total)  
** Elevated alkaline phosphatase levels  
** Elevated gamma-glutamyl transpeptidase levels
** Normal/elevated aspartate aminotransferase and alanine aminotransferase  
** Serum amylase and/or lipase levels are normal/elevated
** CBC shows:
*** mild normocytic normochromic anemia
*** Thrombocytosis    
** Laboratory evidence of malnutrition:
*** Low serum albumin  
*** Low cholesterol level
 
==== CA 19-9 ====
* In cancer patients, CA 19-9 antigen is an oligosaccharide found on circulating mucins.
* CA 19-9 is elevated in case of biliary disease as it is produced within the cells of the biliary tract.
* The reference range of CA 19-9 is less than 35 U/mL.
* Three fourths of the patients with pancreatic carcinoma have elevated CA 19-9 levels.  
* CA 19-9 value of greater than 100 U/mL is highly specific for pancreatic cancer, in the absence of intrinsic liver disease or biliary obstruction.
Role in prognosis
* CA 19-9 levels are of prognostic value:
** Preoperative values above 50 U/mL have higher recurrence.
** High levels indicate poorer outcome and low chance of resectability
Role in treatment
* To determine the resectability potential, CA 19-9 levels are used as an adjunct to imaging studies.
* Staging laproscopy prior to resection is not required in patients presenting with low levels of CA 19-9 (< 100 IU) as they are unlikely to have occult metastatic disease.
Role in assessing response to treatment
* A falling CA 19-9 level is indicative of clinical response to therapy during treatment of pancreatic cancer.  


==References==
==References==

Revision as of 21:16, 15 November 2017

Pancreatic cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pancreatic Cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

Diagnostic study of choice

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pancreatic cancer laboratory tests On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pancreatic cancer laboratory tests

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pancreatic cancer laboratory tests

CDC on Pancreatic cancer laboratory tests

Pancreatic cancer laboratory tests in the news

Blogs on Pancreatic cancer laboratory tests

Directions to Hospitals Treating Pancreatic cancer

Risk calculators and risk factors for Pancreatic cancer laboratory tests

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2];Parminder Dhingra, M.D. [3]

Overview

Laboratory findings consistent with the diagnosis of pancreatic cancer include abnormal liver function tests, elevated serum bilirubin levels (conjugated and total), elevated alkaline phosphatase levels and mild normocytic normochromic anemia. Patients may have evidence of malnutrition and elevated CA 19-9 levels.

Laboratory Findings

  • Routine laboratory tests in pancreatic cancer patients are often non specific.
  • Common abnormalities include:
    • Elevated serum bilirubin (conjugated and total)
    • Elevated alkaline phosphatase levels
    • Elevated gamma-glutamyl transpeptidase levels
    • Normal/elevated aspartate aminotransferase and alanine aminotransferase
    • Serum amylase and/or lipase levels are normal/elevated
    • CBC shows:
      • mild normocytic normochromic anemia
      • Thrombocytosis
    • Laboratory evidence of malnutrition:
      • Low serum albumin
      • Low cholesterol level

CA 19-9

  • In cancer patients, CA 19-9 antigen is an oligosaccharide found on circulating mucins.
  • CA 19-9 is elevated in case of biliary disease as it is produced within the cells of the biliary tract.
  • The reference range of CA 19-9 is less than 35 U/mL.
  • Three fourths of the patients with pancreatic carcinoma have elevated CA 19-9 levels.
  • CA 19-9 value of greater than 100 U/mL is highly specific for pancreatic cancer, in the absence of intrinsic liver disease or biliary obstruction.

Role in prognosis

  • CA 19-9 levels are of prognostic value:
    • Preoperative values above 50 U/mL have higher recurrence.
    • High levels indicate poorer outcome and low chance of resectability

Role in treatment

  • To determine the resectability potential, CA 19-9 levels are used as an adjunct to imaging studies.
  • Staging laproscopy prior to resection is not required in patients presenting with low levels of CA 19-9 (< 100 IU) as they are unlikely to have occult metastatic disease.

Role in assessing response to treatment

  • A falling CA 19-9 level is indicative of clinical response to therapy during treatment of pancreatic cancer.

References


Template:WikiDoc Sources